{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T21:04:12Z","timestamp":1771016652367,"version":"3.50.1"},"reference-count":30,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1999,2,1]]},"abstract":"<jats:sec>\n                  <jats:title>Objective.<\/jats:title>\n                  <jats:p>This survey estimated the frequency of use and adverse events associated with cisapride treatment of premature newborns in intensive care units. It was initiated in response to a warning issued in Canada cautioning against cisapride treatment of premature infants of &amp;lt;36 weeks' gestation and &amp;lt;3 months of age.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methodology.<\/jats:title>\n                  <jats:p>Surveys were mailed to 105 neonatology training program directors to obtain the total number of neonatal intensive care unit (NICU) admissions, the number of admissions of infants of &amp;lt;36 weeks' gestation, the number of years that cisapride had been used, the estimated percent\/number of premature patients treated with cisapride per year, and the frequency and nature of arrhythmias or other adverse events associated with cisapride treatment. Of 105 programs, 46 responded to a single mailing of the first survey. A second survey mailed to the 45 respondents to the first survey sought to determine the indications, diagnostic tests, and dosages used with cisapride treatment of premature newborns. Of the 45 programs, 26 responded to the second survey.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>More than 58\u2009000 premature newborns of &amp;lt;36 weeks' gestation were admitted to the NICUs we surveyed, and \u223c19% were treated with cisapride. No deaths attributable to cisapride were reported among &amp;gt;11\u2009000 preterm newborns treated. Three nonfatal arrhythmias were reported; two associated with 10-fold dosing errors and one with co-treatment with erythromycin, a macrolide antibiotic that reduces the metabolism of cisapride. Diarrhea was reported in 12 patients, and reversible liver enzyme changes were noted in one patient. Typically, cisapride treatment was started in dosages of 0.1 to 0.2 mg\/kg\/dose, repeated every 6 to 8 hours. Treatment usually was begun empirically, without a preceding study to document gastroesophageal reflux. The most frequent indications for cisapride treatment were choking or gagging, with associated apnea, bradycardia, and desaturation. Approximately 50% of patients had discontinued cisapride treatment before discharge. Eighty-four percent of clinicians judged cisapride to be effective for the problems being treated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions.<\/jats:title>\n                  <jats:p>Cisapride treatment of premature infants of &amp;lt;36 weeks' gestation and &amp;lt;3 months of age in NICUs appears to be widespread in the United States. Complications and adverse events were seen when cisapride was administered in excessive dosages or in combination with a drug that inhibits its metabolism and leads to increased serum concentrations. Severe toxicities such as arrhythmias were reported with a frequency of &amp;lt;1\/11\u2009000 NICU admissions. However, in a retrospective survey, episodes of toxicity, including mortality, attributable to cisapride may not have been recognized or reported.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1542\/peds.103.2.469","type":"journal-article","created":{"date-parts":[[2004,8,13]],"date-time":"2004-08-13T23:45:45Z","timestamp":1092440745000},"page":"469-472","source":"Crossref","is-referenced-by-count":64,"title":["Cisapride: A Survey of the Frequency of Use and Adverse Events in Premature Newborns"],"prefix":"10.1542","volume":"103","author":[{"given":"Robert M.","family":"Ward","sequence":"first","affiliation":[{"name":"From the Department of Pediatrics, University of Utah, Salt Lake City, Utah;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James A.","family":"Lemons","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Molteni","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Thomas Jefferson School of Medicine, Philadelphia, Pennsylvania."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[1999,2,1]]},"reference":[{"key":"2021121021172118600_B1","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1542\/peds.88.4.834","article-title":"Gastroesophageal reflux, as measured by 24-hour pH monitoring, in 509 healthy infants screened for risk of sudden infant death syndrome.","volume":"88","author":"Vandenplas","year":"1991","journal-title":"Pediatrics"},{"key":"2021121021172118600_B2","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S0022-3468(81)80698-7","article-title":"Continuous upper esophageal pH monitoring in infants and children with gastroesophageal reflux, pneumonia, and apneic spells.","volume":"16","author":"Ramenofsky","year":"1981","journal-title":"J Pediatr Surg"},{"key":"2021121021172118600_B3","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0022-3476(84)80992-0","article-title":"Awake apnea associated with gastroesophageal reflux: a specific clinical syndrome.","volume":"194","author":"Spitzer","year":"1984","journal-title":"J Pediatr"},{"key":"2021121021172118600_B4","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0022-3476(85)80091-3","article-title":"Apnea associated with regurgitation in infants.","volume":"106","author":"Menon","year":"1985","journal-title":"J Pediatr"},{"key":"2021121021172118600_B5","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0022-3476(89)80351-8","article-title":"Randomized, prospective double-blind trial of metoclopramide and placebo for gastroesophageal reflux in infants.","volume":"115","author":"Tolia","year":"1989","journal-title":"J Pediatr"},{"key":"2021121021172118600_B6","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000480987","article-title":"Use of metoclopramide in preterm infants.","volume":"5","author":"Sankaran","year":"1982","journal-title":"Dev Pharmacol Ther"},{"key":"2021121021172118600_B7","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1136\/adc.62.5.454","article-title":"Cisapride for gastro-oesophageal reflux and peptic oesophagitis.","volume":"62","author":"Cucchiara","year":"1987","journal-title":"Arch Dis Child"},{"key":"2021121021172118600_B8","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1651-2227.1996.tb14079.x","article-title":"Current concepts and issues in the management of regurgitation of infants: a reappraisal.","volume":"85","author":"Vandenplas","year":"1996","journal-title":"Acta Paediatr"},{"key":"2021121021172118600_B9","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/00005176-199010000-00026","article-title":"Long-term use of cisapride (Prepulsid) in premature neonates of &lt;34 weeks gestational age.","volume":"11","author":"Janssens","year":"1990","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2021121021172118600_B10","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0022-3476(88)80345-7","article-title":"Metoclopramide in gastroesophageal reflux of infancy.","volume":"112","author":"Machida","year":"1988","journal-title":"J Pediatr"},{"key":"2021121021172118600_B11"},{"key":"2021121021172118600_B12","doi-asserted-by":"crossref","first-page":"116","DOI":"10.2165\/00003495-199447010-00008","article-title":"Cisapride: an updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders.","volume":"47","author":"Wiseman","year":"1994","journal-title":"Drugs"},{"key":"2021121021172118600_B13","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3810\/pgm.1996.11.110","article-title":"Gastroesophageal reflux disease: the long and the short of therapeutic options.","volume":"100","author":"Brady","year":"1996","journal-title":"Postgrad Med"},{"key":"2021121021172118600_B14","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/00008480-199710000-00008","article-title":"Advances in the diagnosis and treatment of gastroesophageal reflux disease.","volume":"9","author":"Marcon","year":"1997","journal-title":"Curr Opin Pediatr"},{"key":"2021121021172118600_B15","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/BF01953980","article-title":"A proposition for the diagnosis and treatment of gastro-oesophageal reflux disease in children: a report from a working group on gastro-oesophageal reflux disease.","volume":"152","author":"Vandenplas","year":"1993","journal-title":"Eur J Pediatr"},{"key":"2021121021172118600_B16","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/00005176-199604000-00007","article-title":"Cisapride therapy for gastrointestinal disease.","volume":"22","author":"Cucchiara","year":"1996","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2021121021172118600_B17","doi-asserted-by":"crossref","first-page":"F119","DOI":"10.1136\/fn.77.2.F119","article-title":"Cisapride reduces neonatal postoperative ileus: randomised placebo controlled trial.","volume":"77","author":"Lander","year":"1997","journal-title":"Arch Dis Child"},{"key":"2021121021172118600_B18","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1128\/AAC.37.2.265","article-title":"Cytochrome P-450 complex formation by dirithromycin and other macrolides in rat and human livers.","volume":"37","author":"Lindstrom","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121021172118600_B19","first-page":"623","article-title":"Oxidative metabolism of clarithromycin in the presence of human liver microsomes major role for the cytochrome P4503A (CYP3A) subfamily.","volume":"25","author":"Rodrigues","year":"1997","journal-title":"Drug Metab Dispos Biol"},{"key":"2021121021172118600_B20","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/archinte.1995.00430070125014","article-title":"Long QT syndrome during high-dose cisapride.","volume":"155","author":"Bran","year":"1995","journal-title":"Arch Intern Med"},{"key":"2021121021172118600_B21","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0022-3476(96)70409-2","article-title":"Cisapride-induced long QT interval.","volume":"128","author":"Lewin","year":"1996","journal-title":"J Pediatr"},{"key":"2021121021172118600_B22","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1542\/peds.101.6.1053","article-title":"Proarrhythmia associated with cisapride in children.","volume":"101","author":"Hill","year":"1998","journal-title":"Pediatrics"},{"key":"2021121021172118600_B23","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1056\/NEJM199607253350416","article-title":"Cisapride and fatal arrhythmia.","volume":"335","author":"Wysowski","year":"1996","journal-title":"N Engl J Med"},{"key":"2021121021172118600_B24","first-page":"220","article-title":"Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential?","volume":"282","author":"Carlsson","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"2021121021172118600_B25","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/01.CIR.91.12.3010","article-title":"Erythromycin blocks the rapid component of the delayed rectifier potassium current and lengthens repolarization of guinea pig ventricular myocytes.","volume":"91","author":"Daleau","year":"1995","journal-title":"Circulation"},{"key":"2021121021172118600_B26","first-page":"1062","article-title":"Effects of maturation and gastric acidity on gastroesophageal reflux in infants.","volume":"140","author":"Sutphen","year":"1986","journal-title":"Am J Dis Child"},{"key":"2021121021172118600_B27","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/BF00451943","article-title":"Gastro-oesophageal reflux-pathogenesis and clinical implications.","volume":"144","author":"Weihrauch","year":"1985","journal-title":"Eur J Pediatr"},{"key":"2021121021172118600_B28","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1152\/jappl.1989.66.3.1164","article-title":"Pharyngeal fluid clearance and aspiration preventive mechanisms in sleeping infants.","volume":"66","author":"Pickens","year":"1989","journal-title":"J Appl Physiol"},{"key":"2021121021172118600_B29"},{"key":"2021121021172118600_B30"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/103\/2\/469\/888587\/pe029900469o.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/103\/2\/469\/888587\/pe029900469o.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T06:52:09Z","timestamp":1639205529000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/103\/2\/469\/62089\/Cisapride-A-Survey-of-the-Frequency-of-Use-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,2,1]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[1999,2,1]]},"published-print":{"date-parts":[[1999,2,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.103.2.469","relation":{},"ISSN":["1098-4275","0031-4005"],"issn-type":[{"value":"1098-4275","type":"electronic"},{"value":"0031-4005","type":"print"}],"subject":[],"published":{"date-parts":[[1999,2,1]]}}}